Pfizer offers promising long-term dividend investment opportunity

Investor interest surged after the 2024 election but has recently declined. Market indexes are falling as many believe President Trump will impose tariffs on goods from major trading partners. Tech stocks in the S&P 500 have been particularly hard hit, with the "Magnificent Seven" stocks dropping over 15% since their recent peaks. Tesla has seen the largest decline, falling more than half since last December. As the S&P 500 index ended March 18 down 8.6% from its all-time high in February, uncertainty about the trade war looms large. However, investors may find relief with Pfizer, a well-known pharmaceutical company offering a high dividend yield. Pfizer’s stock price is currently low, despite its reputation for reliable dividends. The company has paid growing dividends for 16 years, increasing payouts by about 54% over the past decade. Its current dividend yield stands at 6.6%. The stock price has fallen significantly since reaching its peak a few years ago. Sales of its COVID-19 products, including the Comirnaty vaccine and Paxlovid treatment, have dropped more quickly than many anticipated. Additionally, Pfizer faces challenges as some of its top medications, like Eliquis, near the end of their patent protections. Despite these challenges, Pfizer remains a reliable investment. The company is actively investing in new drugs and the FDA approved several new treatments recently. Management projects stable earnings this year, which will help maintain its dividend payments. With new therapies on the way, Pfizer could likely continue to grow and provide stable returns for investors over the next decade.